Lisata Therapeutics
LSTA
25 hedge funds and large institutions have $1.36M invested in Lisata Therapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
19% more funds holding
Funds holding: 21 → 25 (+4)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.34% less ownership
Funds ownership: 8.44% → 8.11% (-0.34%)
30% less capital invested
Capital invested by funds: $1.93M → $1.36M (-$578K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$33.8K |
| 2 |
Renaissance Technologies
New York
|
+$15.8K |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$11.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$81.1K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$29.1K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$14.9K |
| 4 |
FCMT
Founders Capital Management (Texas)
Houston,
Texas
|
-$740 |
| 5 |
Morgan Stanley
New York
|
-$296 |
LSTA Hedge Fund Activity: Q4 2025 in Review
25 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2025, worth a combined $1.36M — down 30% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LSTA positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Ground Swell Capital, adding an estimated $33.8K. The largest seller was BML Capital Management, cutting an estimated $81.1K.
- 25 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $1.36M of Lisata Therapeutics stock for Q4 2025, down 30% quarter-over-quarter.
- 6 funds opened new Lisata Therapeutics positions in Q4 2025 and 2 closed out, a net change of +4 holders.
- The largest Lisata Therapeutics buyer in Q4 2025 was Ground Swell Capital, an estimated $33.8K added.
- The largest Lisata Therapeutics seller in Q4 2025 was BML Capital Management, an estimated $81.1K sold.
Based on aggregated 13F filings for Q4 2025.